James E. Thompson

7.8k total citations · 1 hit paper
148 papers, 4.6k citations indexed

About

James E. Thompson is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, James E. Thompson has authored 148 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Molecular Biology, 54 papers in Hematology and 20 papers in Oncology. Recurrent topics in James E. Thompson's work include Acute Myeloid Leukemia Research (39 papers), Chronic Myeloid Leukemia Treatments (22 papers) and Melanoma and MAPK Pathways (11 papers). James E. Thompson is often cited by papers focused on Acute Myeloid Leukemia Research (39 papers), Chronic Myeloid Leukemia Treatments (22 papers) and Melanoma and MAPK Pathways (11 papers). James E. Thompson collaborates with scholars based in United States, United Kingdom and Germany. James E. Thompson's co-authors include Stephen C. Fry, Hediye Erdjument‐Bromage, Paul Tempst, Sankar Ghosh, Ronald T. Raines, Craig B. Thompson, Eunice S. Wang, Dean Sheppard, Martin Carroll and Meir Wetzler and has published in prestigious journals such as Cell, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

James E. Thompson

135 papers receiving 4.4k citations

Hit Papers

IκB-β regulates the persistent response in a biphasic act... 1995 2026 2005 2015 1995 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. IκB-β regulates the persistent response in a biphasic activation of NF-κB
    1995 691 citations James E. Thompson, Hediye Erdjument‐Bromage et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James E. Thompson United States 34 2.2k 725 716 658 617 148 4.6k
Joya Chandra United States 40 3.3k 1.5× 200 0.3× 727 1.0× 440 0.7× 964 1.6× 159 5.9k
Gilberto Schwartsmann Brazil 43 2.4k 1.1× 284 0.4× 516 0.7× 647 1.0× 1.8k 2.9× 244 6.2k
Vijay K. Singh United States 46 2.0k 0.9× 298 0.4× 1.1k 1.5× 767 1.2× 797 1.3× 234 6.6k
Joseph Kaplan United States 40 2.1k 0.9× 380 0.5× 1.2k 1.7× 223 0.3× 600 1.0× 191 5.5k
Sharon A. Glynn United States 36 1.6k 0.7× 301 0.4× 596 0.8× 971 1.5× 850 1.4× 76 4.0k
Leo W. J. Klomp Netherlands 55 3.2k 1.4× 593 0.8× 476 0.7× 406 0.6× 3.1k 5.0× 90 8.9k
Vladimir N. Podust United States 43 4.0k 1.8× 213 0.3× 301 0.4× 763 1.2× 1.1k 1.8× 73 5.6k
Leonard Liebes United States 39 2.5k 1.1× 214 0.3× 1.2k 1.7× 388 0.6× 2.1k 3.5× 129 6.2k
Hans Brandstetter Austria 39 2.5k 1.1× 185 0.3× 292 0.4× 712 1.1× 1.3k 2.1× 133 5.1k
Angela Nebbioso Italy 41 4.0k 1.8× 192 0.3× 396 0.6× 482 0.7× 840 1.4× 127 6.0k

Countries citing papers authored by James E. Thompson

Since Specialization
Citations

This map shows the geographic impact of James E. Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Thompson more than expected).

Fields of papers citing papers by James E. Thompson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Thompson. The network helps show where James E. Thompson may publish in the future.

Co-authorship network of co-authors of James E. Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Thompson. A scholar is included among the top collaborators of James E. Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Thompson. James E. Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Daver, Naval, Pau Montesinos, Daniel J. DeAngelo, et al.. (2024). Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. The Lancet Oncology. 25(3). 388–399. 34 indexed citations
2.
Kim, Dong‐Hyun, Hannah Loke, James E. Thompson, et al.. (2024). The dopamine D2-like receptor and the Y-chromosome gene, SRY, are reciprocally regulated in the human male neuroblastoma M17 cell line. Neuropharmacology. 251. 109928–109928. 2 indexed citations
3.
4.
Baron, Jeffrey, et al.. (2023). Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report. Journal of the National Comprehensive Cancer Network. 21(2). 102–107. 2 indexed citations
5.
Awada, Hassan, Elizabeth A. Griffiths, James E. Thompson, et al.. (2023). Outcomes of Extramedullary Acute Myeloid Leukemia with Gemtuzumab Ozogamicin: Real-World Experience. Blood. 142(Supplement 1). 5916–5916. 1 indexed citations
6.
Kasner, Margaret, Molly B. Halloran, Ellen K. Ritchie, et al.. (2022). A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia. Investigational New Drugs. 40(4). 773–781. 3 indexed citations
7.
8.
Vigil, Carlos E., Wei Tan, George Deeb, et al.. (2013). Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age. Leukemia Research. 37(11). 1468–1471. 4 indexed citations
9.
Guidugli, Lucia, V. Shane Pankratz, Namit Singh, et al.. (2012). A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity. Cancer Research. 73(1). 265–275. 89 indexed citations
10.
Erdoğan, Begüm, R. Benjamin Isett, John W. Tobias, et al.. (2011). Diagnostic microRNAs in myelodysplastic syndrome. Experimental Hematology. 39(9). 915–926.e2. 45 indexed citations
11.
Lin, Songnian, Jeffrey J. Hale, Sander G. Mills, et al.. (2009). Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas as potent inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). Bioorganic & Medicinal Chemistry Letters. 19(12). 3238–3242. 18 indexed citations
12.
Tsai, Donald E., Selina M. Luger, Charalambos Andreadis, et al.. (2008). A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Clinical Cancer Research. 14(17). 5619–5625. 29 indexed citations
13.
Thompson, James E., Owain R. Millington, Paul Garside, & James M. Brewer. (2008). What can transgenic parasites tell us about the development of Plasmodium‐specific immune responses?. Parasite Immunology. 30(4). 223–233. 9 indexed citations
14.
Natarajan, S., Luping Liu, James E. Thompson, et al.. (2006). p38 MAP kinase inhibitors. Part 5: Discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold. Bioorganic & Medicinal Chemistry Letters. 16(20). 5468–5471. 11 indexed citations
15.
Thompson, James E.. (1998). The Genesis of the 1906 Trades Disputes Act. Twentieth Century British History. 175–200.
16.
Thompson, James E., et al.. (1995). IκB-β regulates the persistent response in a biphasic activation of NF-κB. Cell. 80(4). 573–582. 691 indexed citations breakdown →
17.
Thompson, James E.. (1990). Case 277/87, Sandoz Prodotti Farmaceutici S.p.a. v. Commission of the European Communities , Judgment of 11 January 1990, (competition – notion of agreement); Case 279/87, Tipp-Ex GmbH & Co. KG v. Commision of the European Communities , Judgment of 8 February 1990.. Common Market Law Review. 27(3). 589–607.
18.
Golomb, Harvey M., A Fefer, David W. Golde, et al.. (1988). Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.. PubMed. 15(5 Suppl 5). 7–9. 38 indexed citations
19.
Thompson, James E., et al.. (1987). La vie et l'œuvre d'Eugène Fromentin. Medical Entomology and Zoology.
20.
Thompson, James E.. (1984). Language in Wycherley's plays : seventeenth-century language theory and drama. University of Alabama Press eBooks. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joya Chandra Breakdown of academic impact, for papers by Gilberto Schwartsmann Breakdown of academic impact, for papers by Vijay K. Singh Breakdown of academic impact, for papers by Joseph Kaplan Breakdown of academic impact, for papers by Sharon A. Glynn Breakdown of academic impact, for papers by Leo W. J. Klomp Breakdown of academic impact, for papers by Vladimir N. Podust Breakdown of academic impact, for papers by Leonard Liebes Breakdown of academic impact, for papers by Hans Brandstetter Breakdown of academic impact, for papers by Angela Nebbioso
Rankless by CCL
2026